D Orazio & Associates Inc. Acquires 33 Shares of Amgen Inc. (NASDAQ:AMGN)

D Orazio & Associates Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.1% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 3,101 shares of the medical research company’s stock after buying an additional 33 shares during the quarter. D Orazio & Associates Inc.’s holdings in Amgen were worth $969,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. TCW Group Inc. grew its holdings in Amgen by 25.1% during the fourth quarter. TCW Group Inc. now owns 174,891 shares of the medical research company’s stock worth $50,376,000 after buying an additional 35,040 shares in the last quarter. Grassi Investment Management bought a new position in Amgen in the 1st quarter valued at $2,283,000. Public Employees Retirement System of Ohio grew its stake in Amgen by 1.6% in the 4th quarter. Public Employees Retirement System of Ohio now owns 281,791 shares of the medical research company’s stock valued at $81,161,000 after purchasing an additional 4,376 shares during the period. Meyer Handelman Co. grew its stake in Amgen by 7.2% in the 2nd quarter. Meyer Handelman Co. now owns 129,831 shares of the medical research company’s stock valued at $40,566,000 after purchasing an additional 8,700 shares during the period. Finally, Chicago Partners Investment Group LLC grew its stake in shares of Amgen by 1.3% during the 4th quarter. Chicago Partners Investment Group LLC now owns 4,543 shares of the medical research company’s stock worth $1,388,000 after acquiring an additional 57 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

AMGN has been the subject of several research reports. Oppenheimer reiterated an “outperform” rating and set a $380.00 price target on shares of Amgen in a research note on Wednesday, August 7th. Royal Bank of Canada increased their price target on Amgen from $332.00 to $362.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 7th. Morgan Stanley dropped their price objective on Amgen from $310.00 to $303.00 and set an “equal weight” rating on the stock in a report on Thursday, July 11th. Bank of America increased their price objective on Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $305.00 price target (down previously from $310.00) on shares of Amgen in a report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average price target of $327.28.

Amgen Stock Up 0.3 %

AMGN stock opened at $329.98 on Thursday. Amgen Inc. has a 1-year low of $249.70 and a 1-year high of $346.85. The business has a fifty day moving average price of $327.34 and a 200-day moving average price of $303.13. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The stock has a market capitalization of $177.01 billion, a P/E ratio of 47.14, a P/E/G ratio of 2.85 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.01 by ($0.04). The company had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue for the quarter was up 20.1% on a year-over-year basis. During the same period in the prior year, the firm posted $5.00 EPS. Equities analysts forecast that Amgen Inc. will post 19.49 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were given a dividend of $2.25 per share. The ex-dividend date was Friday, August 16th. This represents a $9.00 dividend on an annualized basis and a yield of 2.73%. Amgen’s dividend payout ratio (DPR) is presently 128.57%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.